MAI Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$559K	Buy	4,242 +3,814	+891%	+$506K	﹤0.01%	982
2025 Q4	$60.7K	Buy	428 +301	+237%	+$43.6K	﹤0.01%	1901
2025 Q3	$17.8K	Sell	127 -201	-61%	-$27.2K	﹤0.01%	2457
2025 Q2	$41.2K	Buy	328 +165	+101%	+$18.9K	﹤0.01%	1972
2025 Q1	$18K	Sell	163 -117	-42%	-$14.8K	﹤0.01%	2231
2024 Q4	$38.2K	Buy	+280	New	+$34.6K	﹤0.01%	1893
2022 Q3	–	Sell	-6,412	Closed	-$625K	–	1009
2022 Q2	$625K	Hold	6,412	–	–	0.01%	486
2022 Q1	$601K	Buy	6,412 +745	+13%	+$63.1K	0.01%	510
2021 Q4	$483K	Buy	5,667 +355	+7%	+$32.7K	0.01%	588
2021 Q3	$509K	Buy	5,312 +171	+3%	+$16.2K	0.01%	509
2021 Q2	$500K	Sell	5,141 -2	-0%	-$192	0.01%	491
2021 Q1	$500K	Buy	5,143 +762	+17%	+$79.9K	0.01%	475
2020 Q4	$420K	Sell	4,381 -1,075	-20%	-$104K	0.01%	482
2020 Q3	$525K	Buy	+5,456	New	+$631K	0.02%	391